-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
-
Summary
-
Inhibikase Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Investing Activities history and growth rate from 2021 to 2023.
- Inhibikase Therapeutics, Inc. Net Cash Provided by (Used in) Investing Activities for the quarter ending March 31, 2024 was -$3.31M, a 43.3% increase year-over-year.
- Inhibikase Therapeutics, Inc. annual Net Cash Provided by (Used in) Investing Activities for 2023 was $11.7M.
- Inhibikase Therapeutics, Inc. annual Net Cash Provided by (Used in) Investing Activities for 2022 was -$16M.